SCHEMBL18282153

SCHEMBL18282153

COC(=O)c1c(Br)c(C)nn1-c1nc(-c2ccc(Cl)c(C)c2)c(SC(C)C)s1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.33
XIAP P98170 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
TP53 P04637 2/20 0.32
S1PR1 P21453 2/20 0.32
KDM4E B2RXH2 2/20 0.32
PKM P14618 1/20 0.32
RCE1 Q9Y256 1/20 0.32
ABL1 P00519 1/20 0.32
NOTUM Q6P988 1/20 0.32
SLC22A12 Q96S37 2/20 0.31
GABRA2 P47869 1/20 0.31
GABRB2 P47870 1/20 0.31
MAPK7 Q13164 1/20 0.31
MYC P01106 1/20 0.31
WDR5 P61964 1/20 0.31
ADCY10 Q96PN6 1/20 0.30
MEN1 O00255 1/20 0.30
KMT2A Q03164 1/20 0.30
SETD1B Q9UPS6 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18282111 0.94 KDM4E (0.38) MAPTNPSR1S1PR1KDM4EPKM
SCHEMBL18282282 0.93 S1PR1 (0.34) MAPTNPSR1TP53S1PR1KDM4E
SCHEMBL18282103 0.91 RIPK2 (0.35) MAPTNPSR1S1PR1KDM4EPKM
SCHEMBL18282138 0.89 MYC (0.34) MYCWDR5KMT2A
SCHEMBL18282209 0.89 MYC (0.39) MAPTKDM4EPKMSLC22A12MYC
SCHEMBL18281998 0.88 XIAP (0.32) MAPTXIAPTP53S1PR1KDM4E
SCHEMBL18282126 0.88 SLC6A3 (0.36) MAPTKDM4EKMT2A
SCHEMBL18282158 0.86 ALDH1A1 (0.32) MAPTMYCWDR5
SCHEMBL18282243 0.86 MAPK14 (0.36) MAPTKDM4ESLC22A12MEN1KMT2A
SCHEMBL18282078 0.85 ALDH1A1 (0.37) MAPTKDM4EPKMMYCWDR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12150934-B2 Methods of using substituted pyrazole and pyrazole compounds and for treatment of hyperproliferative diseases BANTAM PHARMACEUTICAL, LLC (US) 2024-11-26 US disclosed
US-11602526-B2 Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto BANTAM PHARMACEUTICAL, LLC (US) 2023-03-14 US disclosed
US-20200261424-A1 Substituted Pyrazole and Pyrrole Compounds and Methods for Using Them for Inhibition of Initiation of Translation and Treatment of Diseases and Disorders Relating Thereto BANTAM PHARMACEUTICAL, LLC 2020-08-20 US disclosed
US-20200069656-A1 Methods of Using Substituted Pyrazole and Pyrazole Compounds and for Treatment of Hyperproliferative Diseases BANTAM PHARMACEUTICAL, LLC 2020-03-05 US disclosed
CN-110769823-A Methods of using substituted pyrazole and pyrrole compounds and treating hyperproliferative diseases 班塔姆制药有限责任公司 2020-02-07 CN disclosed
EP-3548024-A2 METHODS OF USING SUBSTITUTED PYRAZOLE AND PYRAZOLE COMPOUNDS AND FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES Bantam Pharmaceutical, LLC (US) 2019-10-09 EP disclosed
US-20180311218-A1 Substituted Pyrazole and Pyrrole Compounds and Methods for Using Them for Inhibition of Initiation of Translation and Treatment of Diseases and Disorders Relating Thereto EGENIX, INC. 2018-11-01 US disclosed
WO-2018102452-A2 METHODS OF USING SUBSTITUTED PYRAZOLE AND PYRAZOLE COMPOUNDS AND FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES BANTAM PHARMACEUTICAL, LLC (US) 2018-06-07 WO disclosed
EP-3303332-A1 SUBSTITUTED PYRAZOLE AND PYRROLE COMPOUNDS AND METHODS FOR USING THEM FOR INHIBITION OF INITIATION OF TRANSLATION AND TREATMENT OF DISEASES AND DISORDERS RELATING THERETO Bantam Pharmaceutical, LLC (US) 2018-04-11 EP disclosed
WO-2016196644-A1 SUBSTITUTED PYRAZOLE AND PYRROLE COMPOUNDS AND METHODS FOR USING THEM FOR INHIBITION OF INITIATION OF TRANSLATION AND TREATMENT OF DISEASES AND DISORDERS RELATING THERETO BANTAM PHARMACEUTICAL, LLC (US) 2016-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200261424-A1 Substituted Pyrazole and Pyrrole Compounds and Methods for Using Them for Inhibition of Initiation of Translation and Treatment of Diseases and Disorders Relating Thereto EIF4A1, EIF4A3, EIF4B MAPT 2284/4885XIAP 1569/4885NPSR1 2217/4885
US-20180311218-A1 Substituted Pyrazole and Pyrrole Compounds and Methods for Using Them for Inhibition of Initiation of Translation and Treatment of Diseases and Disorders Relating Thereto EIF4A3, EIF4A1, EIF4B MAPT 2855/4885XIAP 1812/4885NPSR1 3395/4885
US-20200069656-A1 Methods of Using Substituted Pyrazole and Pyrazole Compounds and for Treatment of Hyperproliferative Diseases KRAS, TP53, CCNA1 MAPT 4869/4885XIAP 181/4885NPSR1 4223/4885
US-12150934-B2 Methods of using substituted pyrazole and pyrazole compounds and for treatment of hyperproliferative diseases KRAS, TP53, CCNA1 MAPT 4869/4885XIAP 181/4885NPSR1 4223/4885
US-11602526-B2 Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto EIF4A1, EIF4A3, EIF4B MAPT 2284/4885XIAP 1569/4885NPSR1 2217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.